INFU
Price
$8.08
Change
+$0.46 (+6.04%)
Updated
Apr 26, 6:59 PM EST
5 days until earnings call
XRAY
Price
$30.57
Change
+$0.22 (+0.72%)
Updated
Apr 26, 6:59 PM EST
5 days until earnings call
Ad is loading...

Analysis and predictions INFU vs XRAY

Header iconINFU vs XRAY Comparison
Open Charts INFU vs XRAYBanner chart's image
InfuSystem Holdings
Price$8.08
Change+$0.46 (+6.04%)
Volume$6.34K
CapitalizationN/A
DENTSPLY SIRONA
Price$30.57
Change+$0.22 (+0.72%)
Volume$603.34K
CapitalizationN/A
View a ticker or compare two or three
INFU vs XRAY Comparison Chart

Loading...

INFUDaily Signal changed days agoGain/Loss if shorted
 
Show more...
XRAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
INFU vs. XRAY commentary
Apr 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INFU is a Hold and XRAY is a StrongSell.

COMPARISON
Comparison
Apr 27, 2024
Stock price -- (INFU: $8.12 vs. XRAY: $30.57)
Brand notoriety: INFU and XRAY are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: INFU: 57% vs. XRAY: 34%
Market capitalization -- INFU: $186.74M vs. XRAY: $6.69B
INFU [@Medical Specialties] is valued at $186.74M. XRAY’s [@Medical Specialties] market capitalization is $6.69B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

INFU’s FA Score shows that 0 FA rating(s) are green whileXRAY’s FA Score has 1 green FA rating(s).

  • INFU’s FA Score: 0 green, 5 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, XRAY is a better buy in the long-term than INFU.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

INFU’s TA Score shows that 4 TA indicator(s) are bullish while XRAY’s TA Score has 4 bullish TA indicator(s).

  • INFU’s TA Score: 4 bullish, 2 bearish.
  • XRAY’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, INFU is a better buy in the short-term than XRAY.

Price Growth

INFU (@Medical Specialties) experienced а -0.98% price change this week, while XRAY (@Medical Specialties) price change was +0.23% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.43%. For the same industry, the average monthly price growth was -5.27%, and the average quarterly price growth was +16.21%.

Reported Earning Dates

INFU is expected to report earnings on Aug 15, 2024.

XRAY is expected to report earnings on Aug 01, 2024.

Industries' Descriptions

@Medical Specialties (+0.43% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for INFU with price predictions.
OPEN
A.I.dvisor published
a Summary for XRAY with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
XRAY($6.69B) has a higher market cap than INFU($187M). INFU has higher P/E ratio than XRAY: INFU (195.13) vs XRAY (19.23). XRAY YTD gains are higher at: -13.680 vs. INFU (-22.960). XRAY has higher annual earnings (EBITDA): 249M vs. INFU (16.2M). XRAY has more cash in the bank: 334M vs. INFU (161K). INFU has less debt than XRAY: INFU (36.3M) vs XRAY (2.3B). XRAY has higher revenues than INFU: XRAY (3.97B) vs INFU (123M).
INFUXRAYINFU / XRAY
Capitalization187M6.69B3%
EBITDA16.2M249M7%
Gain YTD-22.960-13.680168%
P/E Ratio195.1319.231,015%
Revenue123M3.97B3%
Total Cash161K334M0%
Total Debt36.3M2.3B2%
FUNDAMENTALS RATINGS
INFU vs XRAY: Fundamental Ratings
INFU
XRAY
OUTLOOK RATING
1..100
6950
VALUATION
overvalued / fair valued / undervalued
1..100
89
Overvalued
8
Undervalued
PROFIT vs RISK RATING
1..100
72100
SMR RATING
1..100
8891
PRICE GROWTH RATING
1..100
7663
P/E GROWTH RATING
1..100
10085
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (8) in the Medical Specialties industry is significantly better than the same rating for INFU (89). This means that XRAY’s stock grew significantly faster than INFU’s over the last 12 months.

INFU's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as XRAY (100). This means that INFU’s stock grew similarly to XRAY’s over the last 12 months.

INFU's SMR Rating (88) in the Medical Specialties industry is in the same range as XRAY (91). This means that INFU’s stock grew similarly to XRAY’s over the last 12 months.

XRAY's Price Growth Rating (63) in the Medical Specialties industry is in the same range as INFU (76). This means that XRAY’s stock grew similarly to INFU’s over the last 12 months.

XRAY's P/E Growth Rating (85) in the Medical Specialties industry is in the same range as INFU (100). This means that XRAY’s stock grew similarly to INFU’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
INFUXRAY
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
57%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
66%
Momentum
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
63%
MACD
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
54%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 1 day ago
62%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
68%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
58%
Declines
ODDS (%)
Bearish Trend 2 days ago
73%
Bearish Trend 10 days ago
68%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
44%
Aroon
ODDS (%)
Bearish Trend 1 day ago
70%
Bearish Trend 1 day ago
76%
View a ticker or compare two or three
Ad is loading...
INFUDaily Signal changed days agoGain/Loss if shorted
 
Show more...
XRAYDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PFSLX72.690.79
+1.10%
Paradigm Select
FHUMX14.540.07
+0.48%
Federated Hermes US SMID Institutional
MLVMX19.440.05
+0.26%
MFS Low Volatility Equity R1
BARIX103.600.06
+0.06%
Baron Asset Instl
FSTRX31.320.01
+0.03%
Federated Hermes MDT Large Cap Value A

INFU and

Correlation & Price change

A.I.dvisor tells us that INFU and VCYT have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INFU and VCYT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INFU
1D Price
Change %
INFU100%
+6.70%
VCYT - INFU
31%
Poorly correlated
-0.87%
XRAY - INFU
31%
Poorly correlated
+0.72%
NVST - INFU
30%
Poorly correlated
+1.85%
SMTI - INFU
29%
Poorly correlated
+0.43%
BIO - INFU
28%
Poorly correlated
+0.12%
More

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
+0.72%
NVST - XRAY
66%
Loosely correlated
+1.85%
WST - XRAY
51%
Loosely correlated
-2.10%
STAA - XRAY
50%
Loosely correlated
+0.15%
ALGN - XRAY
44%
Loosely correlated
-0.48%
WAT - XRAY
41%
Loosely correlated
+0.96%
More